Therapeutic manipulation of the microbiota: past, present, and considerations for the future

Clinical Microbiology and Infection

Volumn 22, Issue 11, 2016, Pages 905-909

  Young, V B ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Clostridium difficile; Colonization resistance; Faecal microbiota transplant; Microbiome; Microbiota

Indexed keywords

BACTERIAL COLONIZATION; BILE ACID METABOLISM; CLOSTRIDIUM DIFFICILE INFECTION; FECAL MICROBIOTA TRANSPLANTATION; FECES MICROFLORA; HISTORY; HUMAN; MICROBIOME; MICROFLORA; NONHUMAN; PATHOGENESIS; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; SYSTEMATIC REVIEW; THERAPY EFFECT; ANIMAL; CLOSTRIDIUM INFECTIONS; DISEASE MODEL; FECES; INFLAMMATORY BOWEL DISEASES; MICROBIOLOGY; PROCEDURES;

ANIMALS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DISEASE MODELS, ANIMAL; FECAL MICROBIOTA TRANSPLANTATION; FECES; HISTORY, 20TH CENTURY; HUMANS; INFLAMMATORY BOWEL DISEASES; MICROBIOTA;

EID: 84995704497     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2016.09.001     Document Type: Review

References (46)

1. [1] Rao, K., Young, V.B., Fecal microbiota transplantation for the management of Clostridium difficile infection. Infect Dis Clin North Am 29 (2015), 109–122.
2. [2] Brandt, L.J., Fecal microbiota transplant: Respice, adspice, prospice. J Clin Gastroenterol 49:Suppl 1 (2015), S65–S68.
3. [3] Mangiola, F., Ianiro, G., Franceschi, F., Fagiuoli, S., Gasbarrini, G., Gasbarrini, A., Gut microbiota in autism and mood disorders. World J Gastroenterol 22 (2016), 361–368.
4. [4] Zhang, F., Luo, W., Shi, Y., Fan, Z., Ji, G., Should we standardize the 1,700-year-old fecal microbiota transplantation?. Am J Gastroenterol, 107, 2012, 1755 author reply 1755–1756.
5. [5] Eiseman, B., Silen, W., Bascom, G.S., Kauvar, A.J., Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 44 (1958), 854–859.
6. [6] Bartlett, J.G., Onderdonk, A.B., Cisneros, R.L., Kasper, D.L., Clindamycin-associated colitis due to a toxin-producing species of clostridium in hamsters. J Infect Dis 136 (1977), 701–705.
7. [7] Koch, R., An address on bacteriological research. Br Med J 2 (1890), 380–383.
8. [8] Falkow, S., Molecular Koch's postulates applied to bacterial pathogenicity–a personal recollection 15 years later. Nat Rev Microbiol 2 (2004), 67–72.
9. [9] Falkow, S., Molecular Koch's postulates applied to microbial pathogenicity. Rev Infect Dis 10:Suppl 2 (1988), S274–S276.
10. [10] Gevers, D., Knight, R., Petrosino, J.F., Huang, K., McGuire, A.L., Birren, B.W., et al. The Human Microbiome Project: a community resource for the healthy human microbiome. PLoS Biol, 10, 2012, e1001377.
11. [11] Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, T., Mende, D.R., et al. Enterotypes of the human gut microbiome. Nature 473 (2011), 174–180.
12. [12] Rifkin, G.D., Fekety, F.R., Silva, J. Jr., Antibiotic-induced colitis implication of a toxin neutralised by Clostridium sordellii antitoxin. Lancet 2 (1977), 1103–1106.
13. [13] Lusk, R.H., Fekety, R., Silva, J., Browne, R.A., Ringler, D.H., Abrams, G.D., Clindamycin-induced enterocolitis in hamsters. J Infect Dis 137 (1978), 464–475.
14. [14] Pruitt, R.N., Lacy, D.B., Toward a structural understanding of Clostridium difficile toxins A and B. Front Cell Infect Microbiol, 2, 2012, 28.
15. [15] Theriot, C.M., Young, V.B., Interactions between the gastrointestinal microbiome and Clostridium difficile. Annu Rev Microbiol 69 (2015), 445–461.
16. [16] Wilson, K.H., Silva, J., Fekety, F.R., Suppression of Clostridium difficile by normal hamster cecal flora and prevention of antibiotic-associated cecitis. Infect Immun 34 (1981), 626–628.
17. [17] Bassis, C.M., Young, V.B., Schmidt, T.M., Methods for characterizing microbial communities associated with the human body. Fredricks, D.N., (eds.) The human microbiota: How microbial communities affect health and disease, 2013, John Wiley & Sons, Inc, Hoboken, New Jersey, 51–74.
18. [18] Chang, J.Y., Antonopoulos, D.A., Kalra, A., Tonelli, A., Khalife, W.T., Schmidt, T.M., Young, V.B., Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 197 (2008), 435–438.
19. [19] Buffie, C.G., Jarchum, I., Equinda, M., Lipuma, L., Gobourne, A., Viale, A., et al. Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect Immun 80 (2012), 62–73.
20. [20] Seekatz, A.M., Aas, J., Gessert, C.E., Rubin, T.A., Saman, D.M., Bakken, J.S., et al. Recovery of the gut microbiome following fecal microbiota transplantation. MBio 5:3 (2014), e00893–14.
21. [21] Khoruts, A., Dicksved, J., Jansson, J.K., Sadowsky, M.J., Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 44 (2010), 354–360.
22. [22] Wilson, K.H., Freter, R., Interaction of Clostridium difficile and Escherichia coli with microfloras in continuous-flow cultures and gnotobiotic mice. Infect Immun 54 (1986), 354–358.
23. [23] Marvaud, J.C., Mory, F., Lambert, T., Clostridium clostridioforme and Atopobium minutum clinical isolates with vanB-type resistance in France. J Clin Microbiol 49 (2011), 3436–3438.
24. [24] Finegold, S.M., Song, Y., Liu, C., Hecht, D.W., Summanen, P., Könönen, E., et al. Clostridium clostridioforme: a mixture of three clinically important species. Eur J Clin Microbiol Infect Dis 24 (2005), 319–324.
25. [25] Reeves, A.E., Koenigsknecht, M.J., Bergin, I.L., Young, V.B., Suppression of Clostridium difficile in the gastrointestinal tracts of germfree mice inoculated with a murine isolate from the family Lachnospiraceae. Infect Immun 80 (2012), 3786–3794.
26. [26] Lawley, T.D., Clare, S., Walker, A.W., Goulding, D., Stabler, R.A., Croucher, N., et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog, 8, 2012, e1002995.
27. [27] Wahlström, A., Sayin, S.I., Marschall, H.U., Bäckhed, F., Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab 24:1 (2016), 41–50.
28. [28] Sorg, J.A., Sonenshein, A.L., Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol 190 (2008), 2505–2512.
29. [29] Wilson, K.H., Efficiency of various bile salt preparations for stimulation of Clostridium difficile spore germination. J Clin Microbiol 18 (1983), 1017–1019.
30. [30] Theriot, C.M., Koenigsknecht, M.J., Carlson, P.E. Jr., Hatton, G.E., Nelson, A.M., Li, B., et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun, 5, 2014, 3114.
31. [31] Theriot, C.M., Bowman, A.A., Young, V.B., Antibiotic-induced alterations of the gut microbiota alter secondary bile acid production and allow for Clostridium difficile spore germination and outgrowth in the large intestine. mSphere, 1(1), 2016, 10.1128/mSphere.00045-15 pii: e00045-15.
32. [32] Sorg, J.A., Sonenshein, A.L., Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J Bacteriol 192 (2010), 4983–4990.
33. [33] Buffie, C.G., Bucci, V., Stein, R.R., McKenney, P.T., Ling, L., Gobourne, A., et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517 (2015), 205–208.
34. [34] Orenstein, R., Dubberke, E., Hardi, R., Ray, A., Mullane, K., Pardi, D.S., et al. Safety and durability of RBX2660 (microbiota suspension) for recurrent Clostridium difficile infection: Results of the PUNCH CD study. Clin Infect Dis 62 (2016), 596–602.
35. [35] Khanna, S., Pardi, D.S., Kelly, C.R., Kraft, C.S., Dhere, T., Henn, M.R., et al. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J Infect Dis 214 (2016), 173–181.
36. [36] Scaldaferri, F., Pecere, S., Petito, V., Zambrano, D., Fiore, L., Lopetuso, L.R., et al. Efficacy and mechanisms of action of fecal microbiota transplantation in ulcerative colitis: Pitfalls and promises from a first meta-analysis. Transplant Proc 48 (2016), 402–407.
37. [37] Kahn, S.A., Rubin, D.T., When subjects violate the research covenant: Lessons learned from a failed clinical trial of fecal microbiota transplantation. Am J Gastroenterol, 2016 May 10, 10.1038/ajg.2016.153 [Epub ahead of print].
38. [38] Bojanova, D.P., Bordenstein, S.R., Fecal transplants: what is being transferred?. PLoS Biol, 14(7), 2016, e1002503 eCollection 2016. A thought provoking discussion that elements of faeces beyond the bacterial component may play a role in the efficacy of the therapeutic efficacy of faecal transplants.
39. [39] Tauxe, W.M., Haydek, J.P., Rebolledo, P.A., Neish, E., Newman, K.L., Ward, A., et al. Fecal microbiota transplant for Clostridium difficile infection in older adults. Therap Adv Gastroenterol 9:3 (2016), 273–281 A case review that demonstrated that FMT for treatment of CDI in patients aged 65 years or older was generally safe and effective.
40. [40] Ray, A., Jones, C., Does the donor matter? Donor vs patient effects in the outcome of a next-generation microbiota-based drug trial for recurrent Clostridium difficile infection. Future Microbiol 11 (2016), 611–616 A study of a processed faecal microbiota-derived drug for the treatment of recurrent CDI. In this substudy, it was demonstrated that preparation of the therapeutic from four different donors did not have an effect on efficacy.
41. [41] Furuya-Kanamori, L., Doi, S.A., Paterson, D.L., Helms, S.K., Yakob, L., McKenzie, S.J., et al. Upper versus lower gastrointestinal delivery for transplantation of fecal microbiota in recurrent or refractory Clostridium difficile infection: a collaborative analysis of individual patient data from 14 studies. J Clin Gastroenterol, 2016 Mar 11 [Epub ahead of print]. In this meta-analysis of 14 different studies, it is suggested that administration of faecal microbiota transplant via the low gastrointestinal tract is more effective than administration via the upper gastrointestinal route.
42. [42] Lee, C.H., Steiner, T., Petrof, E.O., Smieja, M., Roscoe, D., Nematallah, A., et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 315:2 (2016), 142–149 In this noninferiority trial, 219 patients in a modified intention-to-treat analysis received either fresh or frozen-and-thawed faecal transplant via enema for treatment of recurrent or refractory CDI. There was no difference in efficacy or adverse events between patients who received fresh or frozen FMT.
43. [43] Costello, S.P., Tucker, E.C., La Brooy, J., Schoeman, M.N., Andrews, J.M., Establishing a fecal microbiota transplant service for the treatment of Clostridium difficile infection. Clin Infect Dis 62:7 (2016), 908–914 This paper provides practical advice on setting up a frozen stool bank for use in treating recurrent or refractory CDI. Methodology for donor recruitment, donor screening, stool preparation, and therapeutic delivery is described.
44. [44] Youngster, I., Russell, G.H., Pindar, C., Ziv-Baran, T., Sauk, J., Hohmann, E.L., Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 312:17 (2014), 1772–1778, 10.1001/jama.2014.13875 A clinical trial that demonstrated the efficacy of faeces administered in encapsulated, frozen form for recurrent CDI.
45. [45] Moore, T., Rodriguez, A., Bakken, J.S., Fecal microbiota transplantation: a practical update for the infectious disease specialist. Clin Infect Dis 58:4 (2014), 541–545 Another ‘how-to’ manual for providers utilizing FMT for treatment of recurrent CDI. There is a particular focus on the regulatory aspects of the use of FMT for this indication, including guidance on how to obtain an investigation new drug permit.
46. [46] van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E.G., de Vos, W.M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368:5 (2013), 407–415 The critical randomized trial that demonstrated the efficacy of FMT for the treatment compared with standard treatment with vancomycin.